GEICAM Spanish Breast Cancer Group
Spain's national breast cancer research group, running adjuvant chemotherapy, endocrine and CDK4/6 inhibitor trials across more than 200 hospitals.
Founded in 1995, GEICAM brings together Spain's breast cancer investigators and has enrolled tens of thousands of patients in academic trials. GEICAM 9906 and 9805 shaped adjuvant taxane use, CIBOMA tested maintenance capecitabine in triple-negative disease, and PARSIFAL and FLIPPER studied palbociclib partners in hormone receptor-positive metastatic cancer. GEICAM co-runs global trials with the Breast International Group and the US cooperative groups and maintains the El Álamo registry and a tumour bank. Its chairman is a member of the OnCo people corpus.
- Adjuvant chemotherapy trials (GEICAM 9906, 9805)
- CDK4/6 inhibitor trials (PARSIFAL, FLIPPER)
- El Álamo registry and biobank
- BIG member group
Miguel Martín is the founder of the Spanish breast cancer group GEICAM and a leader of adjuvant chemotherapy trials.
Sara López-Tarruella is a breast oncologist leading GEICAM neoadjuvant studies in triple-negative disease.
Pages like this
not linked directly; found by shared links- InstitutionAustrian Breast & Colorectal Cancer Study Group
Shares Breast International Group (BIG), Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs).
- InstitutionComprehensive Cancer Center Vienna – Medical University of Vienna / AKH
Shares Breast International Group (BIG), Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs).
- PairingCDK4/6 inhibitor + endocrine therapy
Shares Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TrialPALLAS & PENELOPE-B
Shares Miguel Martín, Palbociclib, HR-positive / HER2-negative breast cancer.
- InstitutionEdinburgh Cancer Centre / CRUK Scotland Centre
Shares Breast International Group (BIG), CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- InstitutionInstitut Jules Bordet
Shares Breast International Group (BIG), Endocrine therapy (SERMs, AIs, SERDs), HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- InstitutionBreast Cancer Trials
Shares Breast International Group (BIG), Endocrine therapy (SERMs, AIs, SERDs), HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- PersonAngela DeMichele
Shares Palbociclib, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.